Page 23 - Complete Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jul 07 2021 STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major companion animal markets of the US, Europe, and the United Kingdom. STELFONTA® will be available to Australian veterinarians, including oncologists and general practitioners, in October 2021 through QBiotics’ marketing and distribution partner, Virbac – a global animal health company. BRISB...

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 a

TORONTO, May 28, 2021 (GLOBE NEWSWIRE) — Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage…

In CheckMate -577, Opdivo 1 Approval expands the role of Opdivo in earlier stages of disease, with two indications in the adjuvant setting across three types of cancer 1 PRINCETON, NJ, USA I May 20, 2021 I Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). 1 The approval is based ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Appendix 4C Quarterly Activity Report Mesoblast LimitedApril 30, 2021 GMT NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. “We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ve...